[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematological-malignancies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematological-malignancies":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,44,72,98,119,148,171,182,206,229,263,289,309,332,353,375,394,425,447,469,491,511,538,559,580],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053315","phase-3-long-term-follow-up-of-participants-treated-with-galapagos-chimeric-antigen-receptor-car-t-cell-therapies-100053315",false,"NCT06652633","Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","A Long-term Follow-up Study for Patients Treated With Galapagos CAR T-cell Therapies","Hesperia","Inclusion Criteria:\n\n* All participants who have been treated with a Galapagos CAR T-cell therapy in a clinical trial or Managed Access Program.\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study","ALL","18 Years",{"count":21,"type":22},546,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion.\n\nPer Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all participants exposed to GLPG CAR T-cell therapies for 15 years following their last CAR T-cell infusion to assess the risk of delayed adverse events (AEs) and the long-term benefit\u002Frisk profile and to monitor for replication-competent lentivirus (RCL) and CAR-T cell persistence.",[28],"Hematological Malignancies",[30],"CAR T-cell therapy","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2024-09-09",{"date":39,"type":22},"2039-07",{"name":41,"class":42},"Lakefront Biotherapeutics NV","INDUSTRY",11,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100609902","phase-1-a-first-in-human-trial-of-ds3790a-in-participants-with-hematological-malignancies-100609902","NCT07220616","A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","A Phase 1\u002F2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies","To be eligible to participate in this trial, an individual must meet all the following criteria:\n\n1. Sign and date the ICF, prior to the start of any trial-specific procedures.\n2. Adults \\>=18 years at the time the ICF is signed.\n3. History of one of the histologically documented hematologic malignancies according to the 5th edition of WHO classification as specified in the protocol.\n4. NHL participants only: Agree to provide baseline tumor tissue samples as specified in the protocol.\n5. ECOG PS of 0, 1 or 2 assessed no more than 14 days prior to initiation of trial intervention.\n6. Has adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to initiation of trial intervention as specified in the protocol.\n7. Has an LVEF \\>=50% by either an ECHO or MUGA within 28 days before the trial starts.\n8. Life expectancy of at least 3 months.\n9. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other trial procedures, and trial restrictions.\n10. A woman of childbearing potential is eligible to participate if she meets all criteria as specified in the protocol.\n11. A male participant capable of producing sperm is eligible to participate if he agrees to all criteria as specified in the protocol.\n\nAn individual who meets any of the following criteria will be excluded from participating in this trial:\n\n1. Prior Allo-SCT.\n2. Prior solid organ transplantation.\n3. Inadequate washout period before initiation of trial intervention as specified in the protocol.\n4. Evidence of brain or leptomeningeal disease (spinal cord or CNS metastases) based on history and physical examination, unless treated and with radiologically documented lack of progression within 4 weeks prior to initiation of trial intervention.\n5. Uncontrolled or significant cardiovascular disease as specified in the protocol.\n6. Any of the following within the past 6 months prior to enrollment: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.\n7. Has a history of (noninfectious) ILD\u002Fpneumonitis that required corticosteroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n8. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder and any autoimmune, connective tissue, or inflammatory disorder with potential pulmonary involvement, or prior pneumonectomy.\n9. Has been diagnosed with another malignancy within the previous 3 years.\n10. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia and lymphocytopenia) not yet resolved to NCI-CTCAE Version 5.0, Grade \\\u003C=1 or baseline.\n11. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.\n12. Has active or uncontrolled HBV, HCV, or HIV infections.",{"count":52,"type":22},420,[54,55],"PHASE1","PHASE2","This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.",[28,58],"B-cell Non-Hodgkin Lymphoma",[28,60,61],"DS3790a","B-cell non-Hodgkin lymphoma","2026-06-23",{"date":64,"type":35},"2026-06-26",{"date":66,"type":35},"2026-01-16",{"date":68,"type":22},"2030-11-30",{"name":70,"class":42},"Daiichi Sankyo",5,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100592400","immunological-impact-of-a-post-cell-therapy-treatment-with-flt3-inhibitors-100592400","NCT06992934","Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors","Non Interventional Study Aiming to Assess the Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors on the Phenotype, the Metabolism, the Function of T-cells and Monocytes and Macrophages","TARGETALLO","Inclusion Criteria:\n\n* Patient \\> 18y\u002Fo\n* Patient who received an allogeneic stem cell transplantation for an acute myeloid leukemia and who will receive gilteritinib as post transplantation maintenance\n* Matched related, matched unrelated, mismatched unrelated and haploidentical donors\n\nExclusion Criteria:\n\n* Minors\n* Pregnant women\n* Patient under 'tutelle', 'curatelle' or in prison\n* Patient who has been treated for a solid tumor in the past 2 years\n* Known human immunodeficiency virus (HIV) infection or HIV-related malignancy\n* Clinically active hepatitis B or hepatitis C infection\n* Known allergy or hypersensitivity to gilteritinib",{"count":81,"type":22},10,[83],"NA","Allogeneic hematopoietic stem cell transplantation (aHSCT) is the only curative option for many hematological maligancies. The main cause of death following HSCT is the relapse of the original disease.\n\nFew strategies have been developed to prevent relapse after bone marrow transplantation. New prophylactic strategies are needed to decrease the relapse incidence without increasing the non-relapse mortality in the post-transplant area. Several drugs are currently being explored as maintenance in several AML subgroups such as FLT3 ITD\u002Fmutated AML.\n\nA specific group of AML patients display the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) or mutation. These recurrent genetic abnormalities account for 30-35% of all AML patients. Because FLT3 is a tyrosine kinase, it can be targeted using tyrosine kinase inhibitors (TKI). Originally limited to first generation sorafenib and Midostaurin, the FLT3 TKI now include second generation Gilteritinib, crenolanib and quizartinib13. Because many FLT3 AML patients would relapse after aHSCT, the use of sorafenib, the only FLT3 TKI available at that time, in a post-transplant setting started to be evaluated.\n\nSorafenib is a multi-kinase inhibitor that not only inhibit FLT3 but also the RAS, RAF, KIT, and the VEGF and platelet-derived growth factor receptor. Several retrospective trials reported the safety and efficiency of a sorafenib maintenance.\n\nIn recent years, a mounting piece of evidence suggests that sorafenib may have an impact on several immune cells as T cell populations, dendritic cells, macrophages and myeloid-derived immunosuppressor cells (MDSC). Other more potent and more specific FLT3 inhibitors are currently under investigation both in combination with chemotherapy before transplantation and as post transplantation maintenance. In this line, crenolanib and Gilteritinib are two potent and more specific TKI that proved more effective than sorafenib in the treatment of FLT3 ITD\u002FTKD relapsed, refractory AML patients. These drugs demonstrated a higher response rate in R\u002FR patients. These two drugs are part of the future standard of care in FLT3 AML but their immunological impact has never been studied.\n\nAt a time where cellular therapies (allogeneic stem cell transplantation but also CAR T cells) and targeted therapies are becoming the central point of cancer treatment, it appears mandatory to better understand the interactions between the two. The goal of our research project which covers fundamental and clinical aspects of AML post-transplant treatments is devoted to a better understanding of the impact of Gilteritinib on the immune cells in order to rationalize their use after aHSCT. A better characterization of the action of these drugs on the immune system is urgently needed to develop new prophylactic strategies which could decrease the relapse incidence without increasing the non-relapse mortality in the post-transplant area. This program is proposed for a period of 3 years, time necessary to perform all the in vitro and ex vivo approaches and to recruit a sufficient number of patients eligible for aHSCT.",[28],"NOT_YET_RECRUITING","2026-06-18",{"date":89,"type":35},"2026-06-22",{"date":91,"type":22},"2026-09",{"date":93,"type":22},"2028-08",{"name":95,"class":96},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":71},"100533364","phase-1-a-study-of-dxc006-in-patients-with-advanced-solid-tumors-and-hematologic-malignancies-100533364","NCT06224855","A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies","An Open-label Dose Escalation and Cohort Expansion Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and and Efficacy of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies","Inclusion Criteria:\n\n1. The patient voluntarily signed the informed consent form and followed the protocol requirements.\n2. Gender is not limited.\n3. Age ≥ 18 years old.\n4. Expected survival time ≥ 3 months.\n5. The Eastern Cooperative Oncology Group (ECOG) score 0-2.\n6. Subjects may provide biopsy or archival tumor tissue samples for the central laboratory to confirm expression levels of Target protein.\n7. Patients with solid tumors or hematologic tumors who have failed standard therapy, including small cell lung cancer, multiple myeloma, neuroblastoma, etc..\n8. Patients who have received ASCT treatment must meet the following conditions:\n\n   1. ASCT \\> 100 days from start of study treatment.\n   2. no active infection.\n9. Toxicity from prior antineoplastic therapy has recovered to Grade ≤ 1 (except alopecia) as defined by NCI-CTCAE v5.0, including peripheral neuropathy ≤ Grade 2.\n10. Organ function must meet the following requirements: blood routine:\n\n(1) Patients with multiple myeloma: absolute neutrophil count (ANC) ≥ 1.0×109\u002FL (previous use of granulocyte colony-stimulating factor \\[G-CSF\\] is allowed, and G-CSF is not allowed within 7 days before laboratory examination during the screening period);Platelet count ≥ 50×109\u002FL (platelet transfusion is not allowed within 7 days before laboratory tests during the screening period).\n\nHemoglobin (HGB) ≥ 75 g\u002FL (prior red blood cell \\[RBC\\] transfusions or recombinant human erythropoietin are allowed; Within 7 days before the laboratory examination during the screening period, red blood cell transfusion is not allowed).\n\n(2) Other patients: Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL, Platelet count ≥ 100×109\u002FL, Hemoglobin (HGB) ≥ 90 g\u002FL Liver: total bilirubin (TBIL) ≤ 1.5×ULN, except for subjects with congenital bilirubinemia, such as Gilbert's syndrome (direct bilirubin ≤ 1.5×ULN); Glutamate aminotransferase (AST) and alanine aminotransferase (ALT) both ≤ 3.0×ULN.\n\nIn the presence of liver metastases, both AST and ALT ≤ 5× ULN Kidney: creatinine clearance (Ccr) ≥ 30mL\u002Fmin in patients with multiple myeloma, Creatinine ≤ 1.5×ULN in other patients.\n\nCoagulation:\n\nInternational Normalized Ratio (INR) ≤ 1.5, Activated partial thromboplastin time (APTT) or prothrombin time (PT) ≤ 1.5× ULN.\n\ncorrected serum calcium ≤ 14 mg\u002FdL (≤ 3.5 mmol\u002FL). left ventricular ejection fraction (LVEF) ≥ 50%. 11. The patient and his\u002Fher spouse agree to take effective contraceptive measures (excluding contraception during the safe period) from the time of signing the informed consent form to 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Within 14 days before the first dose: received plasmapheresis; Treatment with \\> 10 mg of prednisone or equivalent doses of systemic corticosteroids per day for more than 3 consecutive days (short-term use for the prevention of contrast allergy can be enrolled).\n2. Patients have received systemic anti-myeloma therapy or investigational drug therapy within 28 days or 5 half-lives (whichever is shorter) prior to the first dose; Radiotherapy within 14 days prior to the first dose.\n3. Patients have received monoclonal antibody therapy within 30 days before the first dose.\n4. Patients have received autologous hematopoietic stem cell transplantation within 100 days before the first dose.\n5. Patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) or have a history of solid organ transplantation.\n6. Patients have received the same targeted therapy in the past (limited to phase Ia clinical trials).\n7. Patient has symptomatic brain metastases or meningeal metastases.\n8. The patient had symptomatic amyloidosis, active plasma cell leukemia, and active POEMS syndrome at the time of screening.\n9. There is evidence of cardiovascular risk, including any of the following: a. QTcF interval ≥ 470 ms (QT interval must be corrected by Fridericia formula \\[QTcF\\]). b. Evidence of currently clinically significant, untreated arrhythmias, including clinically significant electrocardiogram abnormalities such as degree 2 (Mobitz type II) or degree 3 atrioventricular conduction (AV) block. c. History of myocardial infarction, acute coronary syndrome (including unstable angina pectoris), coronary angioplasty, or stenting or bypass grafting within 6 months prior to screening. d. Grade III or IV heart failure(New York Heart Association Functional Grading System). e. Uncontrolled severe hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100 mmHg).\n10. The patient has difficulty breathing or currently requires continuous oxygen therapy, or currently has active pneumonia or interstitial lung disease (except for mild cases as determined by the investigator).\n11. The patient has a history of other primary malignancies, except the following: cured malignancies with a very low risk of recurrence within 5 years, such as skin basal cell carcinoma and skin squamous cell carcinoma, carcinoma in situ of the cervix or breast.\n12. Patients have severe unhealed wound ulcers or fractures, or have undergone major surgery within 28 days prior to dosing or are expected to undergo surgery during the clinical study.\n13. Previous history of allergy to any component or excipient of DXC006.\n14. Active hepatitis B (HBV-DNA greater than the central upper limit of normal or HBV-DNA testing greater than 1000 copies \u002FmL); Hepatitis C infection (positive for hepatitis C antigen or positive for hepatitis C RNA PCR).\n15. Seropositive for human immunodeficiency virus (HIV); Active syphilis (patients with positive syphilis antibodies can be included); Possible active tuberculosis (chest imaging within 3 months prior to first dosing indicating active tuberculosis infection).\n16. Patients had active bleeding within 30 days prior to screening, or were at risk of massive gastrointestinal bleeding or hemoptysis as determined by researchers; Or have inherited bleeding tendencies or coagulation disorders, or bleeding symptoms that require other medical intervention.\n17. Severe arteriovenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism, occurred within 6 months before the first dose.\n18. Female patients with a positive serological pregnancy test or who are breastfeeding.\n19. Active infections requiring medical treatment (CTCAE≥2); Uncontrollable pleural fluid, ascites, pericardial effusion requiring repeated drainage;\n20. Received live attenuated vaccine within 28 days before the first dose.\n21. The patient has other conditions that the investigator or sponsor has determined may affect the study.",{"count":106,"type":22},280,[54],"This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a variety of solid tumors, including small cell lung cancer, multiple myeloma, and neuroblastoma, and hematological malignancies.",[110,28],"Advanced Solid Tumors","2026-06-17",{"date":89,"type":35},{"date":114,"type":35},"2024-01-24",{"date":116,"type":22},"2027-12-31",{"name":118,"class":42},"Hangzhou DAC Biotechnology Co., Ltd.",{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100643498","phase-3-acalabrutinib-maleate-and-bortezomib-for-patients-with-hla-antibodies-100643498","NCT07635511","Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies","Acalabrutinib Maleate Monotherapy or in Combination With Bortezomib for Eliminating HLA Antibodies in Patients With Hematologic Malignancies and Platelet Transfusion Refractoriness: a Multicenter, Randomized Controlled Study","AB-HLA-2026","Inclusion Criteria:\n\n* Patients with hematological malignancies and platelet transfusion refractoriness (24-hour CCI \\\u003C 4.5×10⁹\u002FL or PPR \\\u003C 20%), and with the highest MFI of HLA antibodies \\> 8000 ;\n* Age 18-65 years, both male and female;\n* ECOG performance status 0-3;\n* Expected survival \\> 6 months;\n* Patients must be able to understand and be willing to participate in this study, and sign an informed consent form.\n\nExclusion Criteria:\n\n* Hypersensitivity to acalabrutinib, bortezomib, or excipients;\n* Major organ bleeding (central nervous system, lung, intestines) or grade ≥3 bleeding;\n* Hypersplenism;\n* Concurrent use of drugs that may cause excessive platelet consumption (amphotericin B, vancomycin, ATG, interferon, etc.);\n* Disseminated intravascular coagulation, microangiopathic hemolytic anemia;\n* Underlying diseases of vital organs: such as malignant arrhythmia, myocardial infarction, chronic cardiac insufficiency, decompensated liver insufficiency, renal insufficiency, severe coagulation abnormalities, etc.; persistent fever (\\>38.0°C) for more than 3 days; clinically uncontrolled active infection (including bacterial, fungal, or viral infections), but patients under effective drug therapy are not excluded;\n* Concurrent other progressive malignancies;\n* Patients with cardiac insufficiency: ejection fraction (EF) \\\u003C30%, NYHA class ≥III cardiac insufficiency;\n* Pregnant or lactating women;\n* Expected survival \\\u003C60 days;\n* Currently participating in other clinical drug trials.","65 Years",{"count":129,"type":22},42,[25],"Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of bleeding, but is also strongly associated with graft failure and reduced survival after transplantation. HLA class I antibody-mediated alloimmunization is recognized as the most important immunological cause of PTR. HLA antibodies are directly secreted by plasma cells, which are derived from B cells. Therefore, targeting B cells to reduce antibody production is a crucial step in eliminating HLA antibodies. Bruton's tyrosine kinase (BTK) is expressed throughout B cell development from the pre-B cell stage to maturity and supports B cell development, maturation, survival, proliferation, and antibody production by acting as a downstream kinase in the B cell receptor signaling pathway. Bortezomib, a proteasome inhibitor, can selectively induce apoptosis in long-lived plasma cells. The investigators' preliminary exploratory use of a BTK inhibitor in the treatment of PTR with HLA antibodies significantly reduced the mean fluorescence intensity (MFI) of HLA antibodies, improved platelet transfusion outcomes, and demonstrated a favorable safety profile. Based on these findings, the investigators are conducting a prospective, multicenter, randomized controlled two-arm study to investigate the efficacy and safety of acalabrutinib and bortezomib in eliminating HLA antibodies in hematological malignancies patients with PTR.",[28,133,134],"Platelet Transfusion Refractoriness (PTR)","HLA Antibodies",[136,137,138],"hematological malignancies","Platelet transfusion refractoriness","HLA antibodies","2026-06-07",{"date":141,"type":35},"2026-06-09",{"date":143,"type":22},"2026-06-01",{"date":145,"type":22},"2029-05-31",{"name":147,"class":96},"The First Affiliated Hospital of Soochow University",{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":97},"100643343","phase-2-luspatercept-vs-epoetin-in-treating-poor-erythroid-engraftment-for-hematological-malignancies-100643343","NCT07636486","Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies","Inclusion Criteria:\n\n* 18-65 years\n* Hematologic malignancies\n* Poor erythroid engraftment after the first allo-HSCT\n* Complete remission post-transplantation\n* Eastern Cooperative Oncology Group performance status of 0-2\n* Epoetin-naive\n* Endogenous serum erythropoietin concentration \\\u003C500 U\u002FL\n\nExclusion Criteria:\n\n* Life expectancy shorter than 30 days post-transplantation\n* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)\n* Patients with any conditions not suitable for the trial (investigators' decision)",{"count":156,"type":22},90,[55,25],"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.",[160,161,162,28],"Luspatercept","Epoetin","Poor Erythroid Engraftment","2026-06-04",{"date":141,"type":35},{"date":166,"type":22},"2026-06-15",{"date":168,"type":22},"2030-12-31",{"name":170,"class":96},"Nanfang Hospital, Southern Medical University",{"id":172,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":26,"conditions":175,"keywords":176,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":181,"locationsCount":43},"100566242",{"count":21,"type":22},[25],[28],[30],{"date":178,"type":35},"2026-06-08",{"date":37,"type":35},{"date":39,"type":22},{"name":41,"class":42},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100411210","phase-2-a-study-of-talquetamab-in-participants-with-relapsed-or-refractory-multiple-myeloma-100411210","NCT04634552","A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 1\u002F2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma","MonumenTAL-1","Inclusion Criteria:\n\n* Documented initial diagnosis of multiple myeloma according to international myeloma working group (IMWG) diagnostic criteria\n* Part 3: Measurable disease cohort A, cohort B, cohort C and cohort D: multiple myeloma must be measurable by central laboratory assessment; Cohort E: Multiple myeloma must be measurable by local laboratory assessment\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2\n* Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (beta human chorionic gonadotropin \\[hCG\\]) or urine\n* Willing and able to adhere to the prohibitions and restrictions specified in this protocol\n\nExclusion Criteria:\n\n* Part 3 only: Cohort A and Cohort C only: exposed to a CAR-T or T cell redirection therapy at any time. Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months\n* Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy\n* Received a cumulative dose of corticosteroids equivalent to \\>= 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication)\n* Stroke or seizure within 6 months prior to signing the informed consent form (ICF)",{"count":191,"type":22},510,[55],"The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).",[28],[196],"Multiple Myeloma",{"date":198,"type":35},"2026-06-05",{"date":200,"type":35},"2021-02-01",{"date":202,"type":22},"2029-03-30",{"name":204,"class":42},"Janssen Research & Development, LLC",78,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":227,"locationsCount":4},"100640514","risk-prediction-scores-for-cardiotoxicity-in-cancer-patients-treated-with-cardiotoxic-anticancer-therapies-in-europe-100640514","NCT07621289","Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe","EUCARTOXSCORES","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of cancer\n* Planned cardio-oncology follow-up as part of pre-treatment assessment prior to cardiotoxic anticancer therapy, as defined in the 2022 ESC Cardio-Oncology Guidelines\n\nExclusion Criteria:\n\n* Patients for whom 12-month follow-up is planned to be conducted outside the center that performed the baseline pre-treatment evaluation",{"count":214,"type":22},10000,"OBSERVATIONAL","Cancer management has undergone major advances over the past 30 years. Several anticancer therapies are now highly effective, allowing many cancers to become chronic diseases through sequential lines of treatment. However, these therapies may be associated with severe cardiovascular adverse events.\n\nIt is therefore essential to better understand the factors that determine, for a given patient and a given anticancer therapy, the occurrence of cardiovascular toxicity, and ideally to predict which patients are at highest risk.\n\nThe 2022 ESC Cardio-Oncology Guidelines strongly recommend risk stratification prior to the initiation of cardiotoxic anticancer therapies. Current recommendations suggest the use of risk scores known as \"HFA-ICOS\" scores. However:\n\nNot all cardiotoxic anticancer therapies currently have an associated risk score; Existing scores are derived from small retrospective or prospective cohorts (typically fewer than 100 patients), and most have not undergone rigorous validation, leaving considerable room for improvement.\n\nThe EU-CARTOX-SCORES protocol aims to develop new prediction scores for cardiotoxicity occurring within the first year after initiation of cardiotoxic anticancer therapies. This protocol is innovative through the integration of artificial intelligence and\u002For machine learning approaches alongside conventional statistical methods. These models will be interfaced with a dedicated cardio-oncology digital platform (CardioOncoPilot), currently being deployed across the European Union, ensuring standardized and high-quality data collection within routine clinical care.\n\nThis is a prospective, multicenter, observational study designed as a European cardio-oncology registry, involving all European cardiologists using the platform in routine practice. The inclusion period will last 3 years, with a 12-month follow-up for each patient. At the time of data extraction, all available cases recorded in the CardioOncoPilot platform will be analyzed.\n\nOverall, it is anticipated that between 1,000 and 5,000 patients across Europe will be included by the end of 2027. These patients will be managed in cardio-oncology clinics as part of routine care during treatment with cardiotoxic anticancer therapies, with follow-up conducted at the same center throughout the study.\n\nThe primary endpoint will be the occurrence of cardiotoxicity as defined by the 2022 ESC Guidelines. Additionally, the performance of newly developed prediction models will be compared with existing HFA-ICOS risk scores (when available) in the same patient population.\n\nPatients will be followed according to routine clinical practice and in accordance with the 2022 ESC Cardio-Oncology Guidelines, which recommend both a baseline pre-treatment assessment and a follow-up evaluation at 1 year, regardless of the type of cardiotoxic therapy.\n\nPatient management will not be modified by the study. This research will consist solely of secondary use of data collected during routine care.\n\nWe anticipate that this study will significantly improve prognostic risk stratification tools in patients treated with cardiotoxic anticancer therapies, thereby enhancing identification of those at highest risk of clinically relevant cardiovascular adverse events during follow-up.\n\nThis project will be conducted in collaboration with the ESC Council of Cardio-Oncology, chaired by Prof. Teresa Lopez-Fernandez, ensuring optimal dissemination through appropriate scientific channels. The developed scores will be shared with the scientific community, particularly the European Society of Cardiology (ESC), with the aim of informing future guideline updates.",[218,219,220,221,28],"Cancer","Anticancer Treatment","Cardiovascular Disease Risk Factor","Cardiovascular Diseases","2026-05-27",{"date":224,"type":35},"2026-06-02",{"date":89,"type":22},{"date":168,"type":22},{"name":228,"class":96},"University Hospital, Caen",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":237,"conditions":238,"keywords":246,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100229822","study-of-mgus-smoldering-myeloma-early-mds-and-cll-to-assess-molecular-events-of-progression-and-clinical-outcome-100229822","NCT02269592","Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome","Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome","Inclusion Criteria:\n\n* Patients with Known or Suspected Precursor Hematological Cancer\n* Including the following subgroups of diseases:\n\n  * Early MDS, including pathologically-confirmed MDS (IPSS Low\u002FInt-1; IPSS-R Very Low\u002FLow) and idiopathic cytopenias of undetermined significance (ICUS);\n  * Asymptomatic Multiple Myeloma and Waldenstrom Macroglobulinemia such as monoclonal gammopathy of undermined significance (MGUS) or Smoldering Multiple Myeloma (SMM or SWM);\n  * Monoclonal B cell lymphocytosis (MBL);\n  * Early stage asymptomatic low-grade lymphomas; or\n  * Other precursor conditions or clonal genetic abnormalities of the blood\u002Fbone marrow that do not meet criteria for symptomatic hematological malignancy, or patients exposed to prior chemotherapies (e. g., alkylating agents, platinum derivatives, taxanes, topo-2 inhibitors, anti-metabolites, systemic radioisotopes).\n* Patients must be at least 18 years of age to participate in this research.\n* Inclusion of Women and Minorities -- In accordance with NIH guidelines, women and members of minority groups and their subpopulations will be included in this protocol.\n\nExclusion Criteria:\n\n* Patients with Known or Suspected Precursor Hematological Cancer are NOT EXCLUDED\n* Evidence of symptomatic or active hematological malignancy. Patients enrolled on clinical trials for precursor diseases are NOT excluded from this study.",{"count":214,"type":22},"Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered.\n\nSome of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called \"molecular\" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study.\n\nThis research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have cancer now, had it in the past, or are at risk of developing cancer. The participant will not undergo tests or procedures that are not required as part of their routine clinical care. The investigators will ask the participant to provide an additional sample from tissue that is obtained for their clinical care including blood, bone marrow, or tissue sample. The investigators will also ask for a gentle scrape of the inside of their cheek, mouthwash or a skin sample to obtain their germline DNA",[239,240,28,241,242,243,244,245],"Monoclonal Gammopathy of Undetermined Significance (MGUS)","Myelodysplastic Syndromes","B-cell Malignancy, Low-grade","Myelodysplastic Syndrome With Low-grade Lesions","IgG Monoclonal Gammopathy of Uncertain Significance","Smoldering Multiple Myeloma","Waldenstrom Macroglobulinemia",[247,248,249,245,250,251,244,252],"MGUS","Smoldering Myeloma","Acute Myeloid Leukemia","Monoclonal Gammopathy of Undermined Significance","Monoclonal B cell lymphocytosis","Myelodysplastic syndromes","2026-05-04",{"date":255,"type":35},"2026-05-07",{"date":257,"type":35},"2014-08",{"date":259,"type":22},"2030-09",{"name":261,"class":96},"Dana-Farber Cancer Institute",7,{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100634564","complementary-and-alternative-medicine-among-patients-with-hematologic-malignancies-in-france-100634564","NCT07541326","Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France","Use of Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France: a Mixed-methods Study","COMPLHEMATO","Inclusion Criteria:\n\n* Patients diagnosed with acute leukemia, lymphoma, or myeloma who are hospitalized and undergoing treatment at any of the study centers, regardless of the stage of the disease.\n* Patients aged 18 years or older.\n* Patients who are literate in French.\n* Patients who have been informed about the study and have provided their consent to participate.\n* Patients covered by health insurance.\n\nExclusion Criteria:\n\n* Patients with neurocognitive disorders or severe psychiatric conditions.\n* Patients in the terminal stage of the disease.\n* Patients under legal protection measures, such as guardianship or curatorship.\n* Patients participating in an interventional study on the effectiveness of CAM.",{"count":272,"type":22},85,[83],"Integrative medicine promotes the incorporation of elements from complementary and alternative medicines (CAM) into patient care. These approaches are defined as treatments that are not routinely part of conventional medical care (1). CAM practices include osteopathy, acupuncture, aromatherapy, naturopathy, and various energy-based techniques, although their efficacy is not always well-established. Nevertheless, a meta-analysis on the use of CAM in the context of cancer reported a 40% prevalence of use in 2012 (2). Subsequently, a study conducted in France in 2015 revealed an 83% prevalence of CAM use across all types of cancer, underscoring the interest in these therapies (3). CAM is often employed to alleviate side effects of conventional treatments, such as fatigue, nausea, and vomiting. The 2015 French study primarily focused on solid tumors, with hematological malignancies representing only 2% of the cases, thereby limiting the assessment of CAM use in this context (3). Currently, there is no specific data evaluating the use of CAM among patients with hematological malignancies in France.\n\nHematological malignancies, unlike solid tumors, are characterized by their diffuse nature, making their localization and treatment more challenging for patients to comprehend (4). Additionally, a qualitative study the investigators conducted on the spiritual needs of patients recently diagnosed with hematological malignancies identified CAM as an area of interest. Among the ten patients in the study, seven were using CAM and reported an improvement in their spiritual well-being, which is defined as the ability to integrate the meaning and purpose of life into their health experiences, through relationships with themselves, others, art, nature, or a higher entity. This aspect of CAM utilization was not explored in our previous study on the spiritual needs of patients, particularly in understanding their appeal and the motivations of patients to adopt them.\n\nTherefore, it appears crucial to explore this practice, which is known to be common among healthcare providers. Understanding these complementary care pathways would enable their safety (e.g., avoiding or informing about potential drug interactions) and foster the patient-provider relationship around a topic that is sometimes considered taboo (5). Ultimately, this would contribute to better supporting patients within a holistic care perspective.",[28],[277,278,279],"Alternative medicine","complementary medicine","blood disease","2026-04-16",{"date":282,"type":35},"2026-04-21",{"date":166,"type":22},{"date":285,"type":22},"2027-12-15",{"name":287,"class":96},"University Hospital, Limoges",2,{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":308,"locationsCount":97},"100634445","phase-2-luspatercept-in-preventing-poor-erythroid-engraftment-for-hematological-malignancies-with-moderate-to-severe-myelofibrosis-100634445","NCT07539779","Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis","The Efficacy and Safety of Luspatercept in Preventing Poor Erythroid Engraftment After Allo-HSCT for Hematological Malignancies With Moderate to Severe Myelofibrosis: A Prospective, Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n* Age 18-65 years old, gender not restricted;\n* ECOG score 0-2 points;\n* Hematological malignancies with moderate to severe myelofibrosis\n* Willing to undergo the first allo-HSCT with a suitable donor\n* In a CR state before transplantation.\n\nExclusion Criteria:\n\n* Has previously undergone allo-HSCT;\n* ECOG score is 3-5;\n* Expected lifespan after transplantation is less than 30 days;\n* Has severe cardiac dysfunction, severe arrhythmia or severe pulmonary dysfunction (obstructive and\u002For restrictive ventilation disorder);\n* Has severe liver dysfunction, with liver function indicators (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL)) more than twice the upper limit of normal;\n* Has severe renal dysfunction, with creatinine (Cr) more than twice the upper limit of normal or 24-hour creatinine clearance rate (Ccr) lower than 30 ml\u002Fmin;\n* Has severe active bleeding;\n* Patients judged by the investigator to be unsuitable for participating in this trial.",{"count":297,"type":22},196,[55,25],"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with moderate to severe myelofibrosis (MF). Currently, there is a lack of effective prevention strategies for poor erythroid engraftment after transplantation. Luspatercept, a novel TGF-β superfamily signaling pathway modulator, has shown potential in small-sample studies for the treatment and prevention of post-transplant anemia. Given the high proportion and poor prognosis of poor engraftment function in hematological malignancies with moderate to severe myelofibrosis after transplantation, we plan to conduct a prospective, multicenter, randomized controlled study to explore the efficacy and safety of luspatercept in preventing poor erythroid engraftment after allo-HSCT in hematological malignancies with moderate to severe myelofibrosis.",[160,162,28,301],"Myelofibrosis (MF)","2026-04-13",{"date":304,"type":35},"2026-04-20",{"date":306,"type":22},"2026-05-01",{"date":168,"type":22},{"name":170,"class":96},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":97},"100462809","nurse-initiated-conversations-for-early-integration-of-palliative-care-in-pediatric-oncology-100462809","NCT05306509","Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology","Facilitating Early Integration of Palliative Care in Pediatric Oncology: Development and Implementation of a Nurse-initiated Conversation Program for Pediatric Cancer Patients and Their Families","NiCE","Inclusion Criteria:\n\n* Children within eight weeks of initial oncologic diagnosis or within eight weeks of relapse\u002Frecurrent disease diagnosis\n* Children speaking Chinese\n* Children's family caregivers accompanying the child in the hospital (only one family member is eligible to take this role under current hospital policy)\n* Children's family caregivers speaking Chinese\n* Health care providers who are taking care of the eligible children, including but not limited to physicians, nurses, and social workers\n\nExclusion Criteria:\n\n\\- Children who, in the opinion of their physician, are not capable mentally or verbally of participating in the survey or interview",{"count":318,"type":22},120,[83],"This study aims to develop and implement a pediatric palliative care (PPC) program. It is an open-label, randomized trial (2:1 randomization) in pediatric oncology department of Children's Hospital of Fudan University. The intervention group will receive Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE). The control group will receive routine PPC (will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment). The intervention will take 6 months.",[322,28],"Solid Tumor","2026-03-17",{"date":325,"type":35},"2026-03-19",{"date":327,"type":35},"2022-08-01",{"date":329,"type":22},"2026-07-31",{"name":331,"class":96},"Children's Hospital of Fudan University",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":97},"100603512","phase-2-phase-ii-study-of-cd5-car-engineered-il15-transduced-cord-blood-derived-nk-cells-in-conjunction-with-lymphodepleting-chemotherapy-for-the-management-of-aggressive-t-cell-hematological-malignancies-100603512","NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies","Inclusion Criteria:\n\n1. 18-80 years of age\n2. Patients with hematological malignancies with an expression of CD5 in the tumor sample of ≥ 30% measured by immunohistochemistry or flow cytometry.\n3. Patients must meet disease-specific eligibility criteria.\n\n   a. Patients with a history of T-lymphoid malignancies, defined as T cell acute lymphoblastic leukemia\u002Flymphoma (T-ALL\u002FT-LBL), T-PLL, Peripheral T-cell lymphoma (PTCL-NOS), Hepatosplenic gamma\u002Fdelta NHL, AITL, Alk negative\u002F DUSP22 negative ALCL, or other subtypes of T cell NHL with indication for autologous or allogeneic transplant in CR-1 Patients with T-ALL and T-PLL who are in morphologic remission but flow MRD positive are eligible.\n4. Patients should be at least 1 week from last cytotoxic chemotherapy at the time of starting lymphodepleting chemotherapy. Patients may continue tyrosine kinase inhibitors or other targeted therapies until at least three days prior to administration of lymphodepleting chemotherapy.\n5. Localized radiotherapy to one or more disease sites is allowed.\n6. Karnofsky Performance Scale \\> 50%.\n7. Adequate organ function:\n\n   1. Renal: Serum creatinine ≤ 2.0 ULN or estimated Glomerular Filtration Rate (eGFR using the CKI-EPI equation) ≥ 30 ml\u002Fmin\u002F1.73 m2.\n   2. Hepatic: ALT\u002FAST ≤ 3.0 x ULN or ≤ 5 x ULN if documented liver involvement with disease, Total bilirubin ≤ 2.0 ULN, except in subjects with Gilbert's Syndrome in whom total bilirubin must be ≤ 3.0 mg\u002FdL. No history of liver cirrhosis.\n   3. Cardiac: Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion as determined by an ECHO or MUGA, and no uncontrolled arrhythmias or symptomatic cardiac disease.\n   4. Pulmonary: No clinically significant lung involvement, per PI discretion, pleural effusion, baseline oxygen saturation \\> 92% on room air.\n8. Ability to understand and the willingness to sign a written informed consent document.\n9. Weight ≥40 kg.\n10. English and non-English-speaking patients are eligible.\n11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n    * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n    * History of hysterectomy or bilateral salpingo-oophorectomy.\n    * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n    * History of bilateral tubal ligation or another surgical sterilization procedure.\n\n    Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\n    Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of study therapy.\n12. Signed consent to long-term follow-up protocol PA17-0483.\n\nExclusion Criteria:\n\n1. Positive beta HCG in female of child-bearing potential defined as not postmenopausal for 24 months or no previous surgical sterilization or lactating females.\n2. Presence of clinically significant Grade 3 or greater toxicity from the previous treatment, as determined by PI.\n3. Presence of uncontrolled fungal, bacterial, viral, or other infection not responding to appropriate therapy.\n4. Active hepatitis B or C.\n5. HIV with detectable viral load.\n6. Presence of active neurological disorder(s).\n7. Active autoimmune disease within 12 months of enrollment\n8. Active cerebral or meningeal involvement by the malignancy\n9. Active (defined as requiring therapy) acute or chronic GVHD.\n10. Any other malignancy known to be active, except for treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.\n11. Presence of any other serious medical condition that may endanger the patient at the investigator criteria.\n12. Major surgery \\\u003C4 weeks prior to first dose of study drug\n13. Allogeneic SCT or DLI \\\u003C12 weeks prior to first dose of study drug. Recipients of an allogeneic SCT patients should have discontinued all forms of immunosuppression at least 8 weeks prior to enrollment in the study.\n14. Concomitant use of other investigational agents.\n15. Concomitant use of other anti-cancer agents.\n16. Patients receiving systemic steroid therapy at the time of NK cell infusion (physiological substitutive doses are allowed) or have received ATG or lymphocyte immune globulin within 14 days or alemtuzumab within 3 months of enrollment.\n17. Patients receiving immunosuppressive therapy.\n18. Patients with diminished mental capacity will not be enrolled in the study.","80 Years",{"count":340,"type":22},70,[55],"To determine the safety and efficacy (1-year PFS) of iC9\u002FCD5CAR\u002FIL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.",[28],"2026-03-02",{"date":346,"type":35},"2026-03-04",{"date":348,"type":22},"2027-02-28",{"date":350,"type":22},"2032-07-31",{"name":352,"class":96},"M.D. Anderson Cancer Center",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":4},"100620831","early-phase-1-exploratory-study-on-the-treatment-of-recurrent-and-refractory-hematological-malignancies-with-wgb-0302-injection-100620831","NCT07362732","Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection","Inclusion Criteria:\n\n* 1\\. Age range: 18-75 years old, gender not limited;\n* 2\\. Expected survival time exceeds 12 weeks;\n* 3\\. According to the diagnostic criteria of the International Myeloma Working Group (IMWG) for multiple myeloma, the diagnosis is multiple myeloma (MM), and the expression of BCMA target antigen is confirmed by flow cytometry, bone marrow pathology, and immunohistochemistry.\n* 4\\. Having measurable multiple myeloma lesions:\n* 5\\. The physical fitness status score of the Eastern Cancer Collaboration Group (ECOG) is 0 or 1 point;\n* 6\\. Before screening (at baseline), corresponding conditions should be met;\n* 7\\. Male and female patients of appropriate age must use reliable methods of contraception before entering the trial, during the research process until 30 days after discontinuation of medication; Reliable contraceptive methods will be determined by the primary researchers or designated personnel;\n* 8\\. Those who can understand this experiment and have signed the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Accompanied by other uncontrolled malignant tumors;\n* 2\\. Previously received chimeric antigen receptor therapy or other transgenic T cell therapy less than 6 months after the first administration;\n* 3\\. Have received any anti myeloma treatment (including but not limited to chemotherapy, targeted therapy, immunotherapy, radiation therapy \\[excluding local radiotherapy for pain control\\], etc.) within 14 days prior to the first use of medication;\n* 4\\. Known history of HIV or hepatitis B (HBsAg positive and HBV DNA reaching the detection limit) or hepatitis C virus (anti HCV positive) infection;\n* 5\\. Participants with a history of CNS lymphoma, malignant cells in cerebrospinal fluid, or brain metastases;\n* 6\\. Within 14 days prior to enrollment, there is an uncontrolled active infection. Note: If there is no evidence of active infection within 72 hours before enrollment, subjects who continue to use prophylactic antibiotics, antifungal drugs, or antiviral drugs are allowed;\n* 7\\. Emergency treatment is required due to the impact of tumor masses, such as intestinal obstruction or vascular compression;\n* 8\\. Suffering from serious diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, poorly controlled hypertension, or other uncontrolled active diseases that hinder participation in the trial;\n* 9\\. Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial\u002Fvenous thromboembolism events occurred within 30 days prior to enrollment. If receiving anticoagulant therapy, the treatment dose of participants must reach a stable level before enrollment;\n* 10\\. Long term use of immunosuppressants due to autoimmune diseases or organ transplantation, except for recent or current inhaled corticosteroid therapy;\n* 11\\. Any pregnant or breastfeeding woman, or participant who plans to conceive during or within 18 months after treatment;\n* 12\\. The researcher believes that there are any other factors that are not suitable for the study participants to enter this trial.","75 Years",{"count":361,"type":22},20,[363],"EARLY_PHASE1","At present, the treatment of multiple myeloma (MM) has evolved from traditional chemotherapy to a comprehensive model that includes targeted drugs, immunotherapy, etc. However, the prognosis of recurrent\u002Frefractory MM patients remains severe. For patients who are already resistant to multiple major drugs such as proteasome inhibitors, immunomodulators, and CD38 monoclonal antibodies, the prognosis is particularly poor. B-cell maturation antigen (BCMA) plays a crucial role in regulating B cell proliferation and survival. BCMA is expressed in various hematological malignancies such as multiple myeloma and has become an important biomarker, promising therapeutic target, and research direction for these diseases.\n\nThe advent of COVID-19 vaccine has brought LNP mRNA technology into the public's view. After years of development, it not only shines brilliantly in COVID-19 vaccine, but also is widely used in the treatment and exploration of cancer, rare diseases and other fields. The core of LNP mRNA technology targeting BCMA is to encapsulate the mRNA encoding specific proteins (such as anti BCMA related proteins) in lipid nanoparticles and deliver them to the body through intravenous or intramuscular injection. The experimental drug WGb 0302 injection is a BCMA based messenger RNA (mRNA) therapeutic drug, formed by loading mRNA encoding BCMA receptor related proteins onto lipid nanoparticles (LNP).",[28],"2026-01-22",{"date":368,"type":35},"2026-01-23",{"date":370,"type":22},"2026-02-01",{"date":372,"type":22},"2028-12-31",{"name":374,"class":96},"Sichuan University",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":381,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":4},"100620821","early-phase-1-exploratory-study-on-in-vivo-car-t-therapy-targeting-cd20-for-the-treatment-of-hematological-malignancies-100620821","NCT07362602","Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies","Inclusion Criteria:\n\n* 1\\. Age range of 18-70 years old, gender not limited;\n* 2\\. Expected survival time exceeds 12 weeks;\n* 3\\. Diagnosed with blood system tumors such as CD20+B-cell lymphoma or lymphocytic leukemia and meeting the corresponding previous treatment requirements;\n* 4\\. There are assessable lesions (applicable only to lymphoma patients);\n* 5\\. The physical fitness status score of the Eastern Cancer Collaboration Group (ECOG) is 0 or 1 point; Before screening (at baseline), corresponding requirements should be met;\n* 7\\. Male and female patients of appropriate age must use reliable methods of contraception before entering the trial, during the research process until 30 days after discontinuation of medication; Reliable contraceptive methods will be determined by the primary researchers or designated personnel;\n* 8\\. Those who can understand this experiment and have signed the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Accompanied by other uncontrolled malignant tumors;\n* 2\\. Received chimeric antigen receptor therapy or other transgenic T cell therapy within 6 months;\n* 3\\. Known history of HIV or hepatitis B (HBsAg positive and HBV DNA reaching the detection limit) or hepatitis C virus (anti HCV positive) infection;\n* 4\\. Participants with a history of CNS lymphoma, malignant cells in cerebrospinal fluid, or brain metastases;\n* 5\\. Participants with atrial or ventricular involvement;\n* 6\\. Emergency treatment is required due to the impact of tumor masses, such as intestinal obstruction or vascular compression;\n* 7\\. Suffering from serious diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage, poorly controlled hypertension, or other uncontrolled active diseases that hinder participation in the trial;\n* 8\\. Unstable pulmonary embolism, deep vein thrombosis, or other major arterial\u002Fvenous thromboembolism events occurred within 30 days prior to enrollment. If receiving anticoagulant therapy, the treatment dose of participants must reach a stable level before enrollment;\n* 9\\. For those who have been using immunosuppressants for a long time after organ transplantation, except for recent or current inhaled corticosteroid therapy;\n* 10\\. Any pregnant or breastfeeding woman, or participant who plans to conceive during or within 18 months after treatment;\n* 11\\. Within 14 days prior to enrollment, there is an active or uncontrollable infection that requires systemic treatment (excluding simple urinary tract infections or upper respiratory tract infections).\n* 12\\. The researcher believes that there are any other factors that are not suitable for the study participants to enter this trial.","70 Years",{"count":383,"type":22},47,[363],"Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed\u002Frefractory patients still faces significant challenges. CD20 is a transmembrane protein highly expressed on the surface of B cells, almost penetrating the precursor, mature, and activated stages of B cells, but lacking in plasma cells, making it an ideal target for B cell malignancies.\n\nIn recent years, the breakthrough development of in vivo CAR-T therapy has overturned the traditional paradigm of in vitro CAR-T technology. The core principle is to directly deliver the gene encoding chimeric antigen receptor (CAR) to T cells in the patient's body through gene delivery vectors, without the need for in vitro isolation, modification, and amplification processes, and to complete the gene reprogramming of T cells in vivo. At present, the mainstream carrier technologies for CAR-T therapy in vivo are divided into two categories: lentiviral carriers and lipid nanoparticle (LNP) carriers. LNP carriers have significantly broken through the clinical bottlenecks of traditional CAR-T in terms of cost and accessibility, safety, and timeliness.\n\nThis experimental drug is a CD20 based messenger ribonucleic acid (mRNA) therapeutic drug, which is an injection formed by loading mRNA onto lipid nanoparticles (LNP). It has shown efficient B-cell clearance activity and good safety in non clinical settings, supporting further clinical exploration in B-cell hematological malignancies. It is expected to provide an innovative, safe, and accessible immunotherapy for B-cell hematological malignancies and bring better clinical benefits to more patients with B-cell hematological malignancies.",[28],"2026-01-15",{"date":368,"type":35},{"date":390,"type":22},"2026-01-26",{"date":372,"type":22},{"name":393,"class":96},"The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":402,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":97},"100577507","phase-2-optimizing-gvhd-prophylaxis-after-allogeneic-hematopoietic-cell-transplantation-100577507","NCT06799195","Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation","A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial","PTCYGVHD","Inclusion criteria:\n\n* Adults aged 60 years or older\n* Diagnosis of a hematological malignancy or other serious hematological disorder that requires an allogeneic hematopoietic cell transplantation\n* Planned to receive any reduced-intensity conditioning regimen (any graft source is acceptable) and availability of human leukocyte antigen (HLA)-matched donor at HLA loci A, B, C, and HLA-DR beta chain antigen (DRB1)\n* Karnofsky Performance Status (KPS) of 70% or higher.\n\nExclusion criteria:\n\n* Previous history of one or more prior allogeneic stem cell transplants (i.e., second or third allogeneic transplant)\n* Planned use of high doses of cyclophosphamide (e.g., a total cyclophosphamide dose of approximately 50 mg\u002Fkg or more) as part of the conditioning regimen prior to allogeneic stem cell transplant. A lower dose of cyclophosphamide (e.g., fludarabine, cyclophosphamide, and low-dose total body irradiation regimen that uses 2 doses of cyclophosphamide at 14.5 mg\u002Fkg) is acceptable.\n* Known diagnosis of liver cirrhosis or other advanced liver disease that may impact cyclophosphamide metabolism.\n* Diagnosis of myelofibrosis\n* Creatinine clearance less than 40 mL\u002Fmin\u002F1.73 m², which may increase the risk of hemorrhagic cystitis with post-transplant cyclophosphamide (PTCy)\n* Systolic cardiac dysfunction with an ejection fraction of less than 45%.\n* Use of a haploidentical or mismatched donor.\n* Any other condition judged by the physician to increase the risk of toxicities associated with PTCy.","60 Years",{"count":404,"type":22},126,[55],"This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.",[28,408],"Graft-versus-Host Disease (GVHD)",[410,411,412,413,414,415],"Allogeneic Hematopoietic Stem Cell Transplantation","GVHD Prophylaxis","Sirolimus","Mycophenolate Mofetil (MMF)","Health-Related Quality of Life (HRQoL)","Randomized Controlled Trial","2025-12-08",{"date":418,"type":35},"2025-12-15",{"date":420,"type":35},"2025-06-23",{"date":422,"type":22},"2031-11",{"name":424,"class":96},"University of Nebraska",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100533379","m-2018-334-in-hematological-malignancies-100533379","NCT06225050","M-2018-334 in Hematological Malignancies","A Single-center Pilot Study Using TCRα\u002Fβ and CD45RA Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Cell Transplantation in Adults(HAPLO2022)","HAPLO2022","Inclusion Criteria:\n\n* Patients, between 18 years to 75 years of age, with high-risk hematological malignancy requiring an allogeneic hematopoietic stem cell transplantation (AlloHCT), but do not have an HLA-matched donor available\n\nExclusion Criteria:\n\n* \\\u003C3 months after preceding autologous transplantation or prior AlloHCT\n* History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukoencephalopathy, active CNS infection)\n* Active fungal infections with radiological and clinical progression\n* Liver function abnormalities with bilirubin \\>2 mg\u002FdL and elevation of transaminases higher than 400 U\u002FL\n* Chronic active viral hepatitis\n* Cardiac dysfunction: adult patients ejection fraction \\\u003C50% on echocardiography\n* Patients with uncontrolled, \\>grade II hypertension (per Common Toxicity Criteria, CTC)\n* Creatinine clearance \\\u003C60 mL\u002Fmin\u002F1.73m2\n* Respiratory failure necessitating supplemental oxygen\n* HIV infection\n* Positive anti-donor HLA antibody\n* Treatment with checkpoint inhibitors in the period between 3 months prior to and 3 months after transplantation\n* Female patients who are pregnant or breast feeding, or adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter. Note: Women of childbearing potential must have a negative serum pregnancy test at study entry\n* Concurrent severe or uncontrolled medical disease (e.g., uncontrolled diabetes, myocardial infarction within 6 months prior to the study) which by assessment of the treating physician could compromise participation in the study\n* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism\u002Fdrug addiction).\n* Patients unwilling or unable to comply with the protocol or unable to give informed consent\n* Treatment with any investigational product within 4 weeks prior to study treatment",{"count":434,"type":22},18,[83],"This is a single-center, open-label, single-arm, pilot clinical study using TCRα\u002Fβ and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.",[28],"2025-11-25",{"date":440,"type":35},"2025-12-03",{"date":442,"type":22},"2026-02-28",{"date":444,"type":22},"2029-02-28",{"name":446,"class":42},"Miltenyi Biomedicine GmbH",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":468},"100545835","phase-1-a-clinical-study-of-hmpl-506-in-patients-with-hematological-malignancies-100545835","NCT06387082","A Clinical Study of HMPL-506 in Patients With Hematological Malignancies","A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of HMPL-506 in Patients With Hematological Malignancies","Inclusion Criteria:\n\n* Subjects must meet all of the following criteria to be eligible for enrolment.\n\n  1. Having understood this study adequately and being voluntary to sign the ICF;\n  2. Age ≥18 years;\n  3. 1\\) Dose escalation phase: patient with MLL-rearranged and\u002For NPM1-mutant relapsed\u002Frefractory AML or ALL (confirmed as per the 2022 World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia): 2) Dose expansion phase: approximately 10 to 20 patients will be enrolled in each of the following cohorts\n\n     * MLL-rearranged and\u002For NPM1-mutant relapsed\u002Frefractory AML\n     * MLL-rearranged relapsed\u002Frefractory ALL\n     * Relapsed\u002Frefractory MM (which can be screened and enrolled without biomarker testing), and AML harboring genetic alterations such as NUP214 or NUP98 fusion\n  4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2;\n  5. Agree to undergo bone marrow aspiration and\u002For biopsy before and during treatment;\n  6. Women patients of childbearing potential must agree to use highly effective contraceptive methods from screening until 30 days after discontinuation of study treatment, and their male partners must use condoms. See Appendix 11 (Definition of Women of Childbearing Potential \\[WOCBP\\] and Acceptable and Unacceptable Contraceptive Methods) for more details. And women patients of childbearing potential should agree not to donate eggs (or oocytes) for reproductive purposes during this period.\n  7. Male patients with a female partner of childbearing potential must agree to use condoms when having intercourse during the study and within 30 days after discontinuation of the investigational product. Patients should avoid sperm donation or freezing of sperm during the study and within 30 days after discontinuation of the investigational product.\n\nExclusion Criteria:\n\n* Subjects will be excluded from this study project if they meet any of the following criteria:\n\n  1. Patients who have previously received treatment with menin inhibitors and experienced progression during treatment;\n  2. Patients with definite active central nervous system (CNS) leukemia (prior CNS leukemia has been treated and controlled, but a cerebrospinal fluid test through lumbar puncture is required at screening to confirm the absence of CNS involvement);\n  3. Serum total bilirubin (TBIL) \\> 1.5 × the upper limit of normal (ULN), with the exception of the following patients:\n\n     • Patients with Gilbert's disease, with normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and serum TBIL ≤ 3 × ULN\n  4. ALT or AST \\> 3 × ULN in the absence of liver involvement with leukemia or ALT or AST \\> 5 × ULN in the presence of liver involvement with leukemia (the latter criterion is not applicable in the dose escalation phase);\n  5. Glomerular filtration rate or creatinine clearance estimated using Cockcroft-Gault formula \\\u003C 50 mL\u002Fmin.\n  6. International normalized ratio (INR) \\> 1.5 × ULN or activated partial thromboplastin time (aPTT) \\> 1.5 × ULN; this criterion is not applicable in patients who are receiving anticoagulant therapy.\n  7. Known history of clinically significant liver disease, including viral hepatitis or other types of hepatitis:\n\n     * Patients with hepatitis B (HBV) (HBsAg or HBcAb positive) can be enrolled if they test negative for HBV DNA by PCR, but the HBV DNA test should be performed every cycle\n     * Patients with hepatitis C (HCV) can be enrolled if they test negative for HCV RNA by PCR.\n  8. Known human immunodeficiency virus (HIV) infection.\n  9. Women who are pregnant (with a positive pregnancy test before administration) or breastfeeding.\n  10. History of stroke or intracranial hemorrhage within 6 months prior to the first dose of the investigational product.\n  11. Patients with other primary malignancies within the last 5 years, but patients with the following non-invasive tumors that have been treated with curative intent are exceptions: basal cell carcinoma of skin, squamous cell carcinoma of skin, in situ carcinoma of cervix and breast cancer in situ.\n  12. Patients who meet any of the following cardiac function-related criteria:\n\n      * Any clinically significant abnormal heart rhythm or conduction requiring clinical intervention.\n      * Hereditary long QT syndrome or QTcF \\> 470 msec.\n      * Clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or above congestive heart failure, left ventricular ejection fraction (LVEF) \\\u003C 50%, or uncontrolled hypertension (systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg), or mean heart rate \\> 100 beats\u002Fmin on triplicate electrocardiograms (ECGs) at screening.\n  13. Receipt of systemic anti-tumor therapy or radiotherapy within 2 weeks prior to initiation of study treatment:\n\n      * For patients with increased peripheral white blood cell count (WBC \\> 25 × 109\u002FL), use of hydroxycarbamide is allowed to control peripheral WBC before enrollment and during HMPL-506 treatment.\n      * Prophylactic intrathecal injection of chemotherapy drugs (cytarabine, dexamethasone and methotrexate) to prevent CNS leukemia is allowed.\n  14. Patients who have received HSCT within 60 days before initiation of study treatment, or are receiving immunosuppressive therapy after HSCT at screening, or require medical intervention to control graft versus host disease (GVHD):\n\n      • Patients who use fixed-dose oral glucocorticoids and\u002For topical glucocorticoids for the treatment of skin GVHD can be enrolled.\n  15. Patients who have received treatment with herbal and traditional medicines\u002Ftheir active ingredients with definite anti-tumor activity within 1 week before initiation of study treatment.\n  16. Use of potent inducers or inhibitors of CYP3A4 within 2 weeks (3 weeks for St John's wort) or 5 half-lives (whichever is longer) before initiation of study treatment.\n  17. An interval of less than 2 weeks from the last dose of any small molecular drug or of less than 4 weeks from the last dose of any macromolecular drug (e.g., antibody drugs) administered during previous participation in other drug clinical trials before treatment initiation in this study.\n  18. Patients who have undergone major surgery within 4 weeks prior to the first dose of the investigational product.\n  19. Toxicities from previous anti-tumor treatments have not yet recovered to Grade ≤ 1 (excluding alopecia).\n  20. Patients with uncontrolled active infection requiring hospitalization or intravenous antibiotics (defined as persistent signs\u002Fsymptoms related to the infection without improvement despite receipt of appropriate anti-infection therapy and\u002For other treatments); or unexplained pyrexia with a temperature above 38.5℃ during the screening period (only patients with tumor fever as judged by the investigator can be enrolled);\n\n      • Patients with neutropenia who, in the opinion of the investigator, require prophylactic intravenous antibiotics can be enrolled\n  21. Presence of conditions that may affect the absorption of the investigational product as judged by the investigator, such as inability to take drugs orally, past surgery history or severe gastrointestinal diseases including dysphagia and active gastric ulcer.\n  22. Patients with poor compliance who are judged by the investigator as not suitable for participation in this clinical study.\n  23. Any other disease, metabolic abnormality, physical examination abnormality or clinically significant laboratory test abnormality, based on which the investigator has reason to suspect that the patient has certain disease or condition that is not suitable for treatment with the investigational product, or that will affect the interpretation of study results or will put the patient at high risk.",{"count":455,"type":22},132,[54],"This is a Phase 1, multicenter, open-label clinical study of HMPL-506 administered orally in the treatment of hematological malignancies. Only eligible patients who provide the signed informed consent form (ICF) can be enrolled in this study. The study consists of two phases, i.e., a dose escalation phase and a dose expansion phase. The study is expected to enroll approximately 60 to 132 patients, including approximately 30 to 38 patients in the dose escalation phase and approximately 30 to 72 patients in the dose expansion phase.",[28],"2025-09-26",{"date":461,"type":35},"2025-09-29",{"date":463,"type":35},"2024-05-27",{"date":465,"type":22},"2027-12-08",{"name":467,"class":42},"Hutchmed",16,{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":338,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":490},"100495244","phase-1-the-study-of-icp-248-in-patients-with-mature-b-cell-malignancies-100495244","NCT05728658","The Study of ICP-248 in Patients With Mature B-cell Malignancies","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients With Mature B-cell Malignancies","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 80 years.\n2. One of the following histopathologically and\u002For flow cytometry-confirmed diseases according to the 2016 World Health Organization (WHO) classification criteria for lymphohematopoietic neoplasms or meeting the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria: Histopathologically and\u002For flow cytometry-confirmed CLL\u002FSLL; Pathologically confirmed MCL; Pathologically confirmed B-NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and lymphoplasmacytic lymphoma (LPL).\n3. Relapsed disease or refractory disease\n4. For subjects with B-NHL: Patients must have measurable diseasePatients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤ 2 and a life expectancy of ≥ 6 months.\n5. Adequate hematologic function.\n6. Patients with basically normal coagulation function.\n7. Patients with adequate hepatic, renal, pulmonary and cardiac functions.\n8. CLL\u002FSLL Patients with an absolute lymphocyte count ≥ 50 x 109\u002FL and any lymph nodes ≥ 5 cm in the long diameter or CLL\u002FSLL or B-NHL patients with any lymph nodes ≥ 10 cm in the long diameter will be enrolled in the study after weighing the risks and benefits with the sponsor's MM.\n9. Female patients of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose of the investigational product; patients of childbearing potential (males and females) must agree to use a reliable birth control method (hormonal or barrier method or abstinence) with their partners from signing the ICF until 90 days after the last dose.The last ICP- 248 dose or within one month after the last dose of Orelabrutinib Or within 12 months after the last dose of Rituximab (whichever is longer).\n10. Subjects are able to communicate with the investigator well and to complete the study as specified in the study.\n11. Before the trial, the subjects shall understand the nature, significance, possible benefits, inconveniences and potential risks, as well as the study procedures of the trial in detail and voluntarily sign the written Informed Consent Form (ICF).\n12. Subjects with CLL\u002FSLL must have an indication for treatment as judged by the investigator.\n\nExclusion Criteria:\n\n1. Prior malignancy (other than the disease under study) within 2 years before study entryKnown\n2. Central nervous system involvement by lymphoma\u002Fleukemia\n3. Underlying medical conditions that, in the investigator's opinion, will render the administration of the investigational product hazardous or obscure the interpretation of the safety or efficacy results.\n4. Prior autologous stem cell transplant (unless ≥ 3 months after transplant); or prior chimeric cell therapy (unless ≥ 3 months after cell infusion).\n5. Received a BCL-2 inhibitor prior to initial use of the investigational drug and did not achieve disease remission or disease recurrence\u002Fprogression on treatment; Disease recurrence\u002Fprogression after stopping or ending BCL-2 inhibitor therapy is acceptable.\n6. A history of allogeneic stem cell transplantation.\n7. Anti-cancer therapy within 14 days prior to the first dose of the investigational product\n8. An interval of less than 5 half-lives from the last dose of a strong CYP3A inhibitor or inducer (chemical agent, traditional Chinese medicine and dietary supplement) to the first dose of the investigational product, or a plan to use concurrently medications, dietary supplements or food (e.g., grapefruit or grapefruit juice) with strong CYP3A inhibitory or inductive effect during study participation.\n9. Patients who have undergone major organ surgery (excluding aspiration biopsy) or significant trauma within 28 days prior to the first dose of the investigational product, or who require elective surgery during the trial.\n10. Patients who have received a live attenuated vaccine within 28 days prior to the first dose of the investigational product (except for vaccination to prevent a major public health event).\n11. Presence of active infection that currently requires intravenous systemic anti-infective therapy.\n12. Patients with active hepatitis B or C virus infection.\n13. History of immunodeficiency, including a positive human immunodeficiency virus (HIV) antibody test.\n14. History of significant cardiovascular disease\n15. Patients with previous or concomitant central nervous system disordersHistory or current evidence of severe interstitial lung disease.\n16. ≥ Grade 2 toxicity due to prior anti-cancer therapy at enrollment (except for alopecia, ANC, hemoglobin and PLT). For ANC, hemoglobin and PLT, please follow the inclusion criteria.\n17. History of severe bleeding disorder\n18. Known alcohol or drug dependence.\n19. Presence of mental disorders or poor compliance.\n20. Female patients who are pregnant or lactating.\n21. Unable to swallow tablets or disease significantly affecting gastrointestinal function.\n22. Hypersensitivity to the active substance or excipients of ICP-248 tablets or Orelabrutinib tablets (only applicable to subjects in cohort G\u002FH\u002FJ\u002FK).Severe allergic reaction or intolerance to murine monoclonal antibodies or murine products.\n\n23 Invasive mantle cell lymphoma, such as mother cell subtypes, polymorphic subtypes, or Ki-67 proliferation index\\>50%, must be discussed with the sponsor's medical monitor regarding patient benefits and risks before being included in this study.",{"count":477,"type":22},191,[54],"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.",[28],"2025-09-02",{"date":483,"type":35},"2025-09-08",{"date":485,"type":35},"2023-03-09",{"date":487,"type":22},"2026-10-30",{"name":489,"class":42},"Beijing InnoCare Pharma Tech Co., Ltd.",22,{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":338,"enrollmentInfo":498,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":97},"100602374","18f-pentixafor-pet-in-hematologic-malignancies-100602374","NCT07122674","18F-Pentixafor PET in Hematologic Malignancies","Prospective Clinical Study of 18F-Pentixafor PET Imaging in Hematologic Malignancies","Inclusion Criteria:\n\n1. Age of 18-80 years old, both sexes, with behavioral capacity;\n2. patients with suspected or confirmed hematological malignancies;\n3. 18F-FDG PET or other imaging examinations should be performed according to the treatment plan;\n4. For suspected patients, biopsy or needle biopsy is expected to obtain pathological results;\n5. Can provide informed consent, can understand and comply with the requirements of the study.\n\nExclusion Criteria:\n\n1. pregnant and lactating women;\n2. patients with fear or radiophobia, or with mental disorder or primary affective disorder;\n3. received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv;\n4. received investigational drugs or devices of uncertain efficacy or safety within 1 month;\n5. Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.",{"count":499,"type":22},100,"The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.",[28],"2025-08-07",{"date":504,"type":35},"2025-08-14",{"date":506,"type":35},"2025-07-01",{"date":508,"type":22},"2029-12",{"name":510,"class":96},"First Affiliated Hospital of Zhejiang University",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":97},"100596583","prospective-study-evaluate-the-timing-of-empirical-treatment-for-carbapenem-resistant-bacterials-croeat-study-100596583","NCT07047352","Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study)","A Multi-center Single Arm Prospective Study in Patients of Hematological Malignancies Colonized With Carbapenem-resistant Bacterials to Evaluate the Timing of Empirical Antibiotic Treatment (CROEAT Study)","Inclusion Criteria:\n\n* Patients with hematological malignancies receiving hospital treatment such as chemotherapy\u002Fimmunotherapy\u002Fhematopoietic stem cell transplantation;\n* Those with a recent history of CRO colonization or who have been screened for CRO once a week continuously since admission;\n* Patients assessed by the clinician as being at high risk for CRO infection and requiring intravenous antibiotics covering CRO must meet the following conditions:\n\n  1. Positive active screening for CRO or past CRO infection or local prevalence of CRO (e.g.,CRO detection rate\\>20% among recently hospitalized patients);\n  2. Presence of fever or other possible signs and symptoms of infection;\n  3. Neutropenia(ANC\\\u003C0.1×10\\^9\u002FL)expected to last for ≥7 days,and having any of the following:\n\n     * Gastrointestinal mucositis\u002Fperi-anal infection\u002Fintestinal obstruction;\n\n       * Shock or severe sepsis;\n\n         * Respiratory failure:deoxygenated PaO2\\\u003C60 mmHg or requiring mechanical ventilation;\n\n           * Disseminated intravascular coagulation;\n\n             * Altered mental status or psychiatric abnormalities;\n\n               * Congestive heart failure requiring treatment;\n\n                 * Arrhythmia requiring treatment;\n\n                   * Recurrence of fever shortly after cessation of or during empirical treatment with carbapenems (≤7 days).\n* The patient or their legal guardian has signed the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Individuals who are expected to die within 14 days of hospitalization or have an expected hospital stay of less than 7 days;\n* Any conditions that the investigator believes may increase the risk to the patient;\n* Severe psychological or psychiatric disorders with poor estimated compliance;\n* The presence of any other conditions that the investigator deems unsuitable for participation in this study.",{"count":519,"type":22},91,[83],"In this study, we will evaluate the feasibility and clinical outcomes of risk adaptive empirical therapy to cover carbapenem resistance gram negative bacteria (CRO) in patients with hematological malignancies colonized with CRO. Patients assessed by the clinician as being at high risk for CRO infection and requiring intravenous antibiotics covering CRO must meet the following conditions:\n\n1. Positive active screening for CRO or past CRO infection or local prevalence of CRO (e.g.,CRO detection rate\\>20% among recently hospitalized patients);\n2. Presence of fever or other possible signs and symptoms of infection;\n3. Neutropenia(ANC\\\u003C0.1×10\\^9\u002FL)expected to last for ≥7 days,and having any of the following:\n\n   * Gastrointestinal mucositis\u002Fperi-anal infection\u002Fintestinal obstruction;\n\n     * Shock or severe sepsis;\n\n       * Respiratory failure:deoxygenated PaO2\\\u003C60 mmHg or requiring mechanical ventilation;\n\n         * Disseminated intravascular coagulation;\n\n           * Altered mental status or psychiatric abnormalities;\n\n             * Congestive heart failure requiring treatment;\n\n               * Arrhythmia requiring treatment;\n\n                 * Recurrence of fever shortly after cessation of or during empirical treatment with carbapenems (≤7 days).\n\nThe endpoints of study include incidence of blood-stream infection by CRO, incidence of all causes mortality, incidences of clinical and microbiology response.",[523,524,28],"Carbapenem-resistant Enterobacterales","Neutropenia",[526,136,527,528],"carbapenem-resistant enterobacterales","neutropenia","empirical therapy","2025-06-24",{"date":531,"type":35},"2025-07-02",{"date":533,"type":22},"2025-08-01",{"date":535,"type":22},"2026-06-30",{"name":537,"class":96},"Shanghai Jiao Tong University School of Medicine",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":97},"100562755","national-longitudinal-cohort-of-hematological-diseases-niche---cart-100562755","NCT06607289","National Longitudinal Cohort of Hematological Diseases (NICHE) - CART","Inclusion Criteria:\n\n* Patients with clinically diagnosed hematologic malignancies\n* Patients treated with CAR-T cell therapy\n* Signed the informed consent form",{"count":545,"type":22},1000,"This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.",[28],[549,136],"Chimeric antigen receptors (CAR) T cell","2025-06-15",{"date":552,"type":35},"2025-06-17",{"date":554,"type":35},"2021-06-01",{"date":556,"type":22},"2032-12-31",{"name":558,"class":96},"Institute of Hematology & Blood Diseases Hospital, China",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":567,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":97},"100347363","cord-blood-transplantation-with-myeloablative-conditioning-and-post-transplant-cyclophosphamide-compact-study-100347363","NCT03802773","Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)","Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide in Patients With Hematological Malignancies (The COmPACt Study)","COmPACt","Inclusion Criteria:\n\n* Age: ≥ 18 ≤ 75 years old\n* CB unit transplantation (TNC\\> 2,0 x10\\^7\u002Fkg and \\> 4\u002F6 loci HLA matched)\n* Myeloablative conditioning regimen consisting of either Thiotepa\u002F Busulfan\u002F Fludarabine or TBI\u002F Fludarabine\n* GVHD prophylaxis including PT-Cy (30 mg\u002Fkg or more on days + 3and +5) CSA and MMF\n* Diagnosis of 1 of the following hematological malignancies: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, high risk Acute Lymphoblastic Leukemia (ALL), Bi phenotypic\u002Fundifferentiated leukemia, Chronic Myeloid Leukemia resistant to TK inhibitors, Ph-neg Myeloproliferative Neoplasms, resistant\u002Frelapsing Non-Hodgkin's lymphoma ineligible for an autologous transplant.\n\nExclusion Criteria:\n\n* Positive serologic markers for human immunodeficiency virus (HIV)\n* Acute hepatitis B virus (HBV) or acute hepatitis C virus (HCV) infection",{"count":81,"type":22},"Despite anti-thymocyte globulin has a mainstay role in preventing GvHD (and non-relapse mortality) in CB transplantation, it also induces delayed immune recovery, increased risk of cytomegalovirus and Epstein-Barr virus reactivation, post-transplant lymphoproliferative diseases, overall accounting for increased transplant-related mortality and\u002For increased relapse incidence. All these findings support the use of alternative approaches for in vivo T cell depletion in the setting of CB transplantation.",[570,28],"Cord Blood Transplantation","2025-04-07",{"date":573,"type":35},"2025-04-09",{"date":575,"type":35},"2019-03-14",{"date":577,"type":22},"2025-12-31",{"name":579,"class":96},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":588,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":97},"100475797","apa-and-relaxation-by-biofeedback-in-patients-with-haematological-malignancy-admitted-in-icu-100475797","NCT05475600","APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU","Adapted Physical Activity and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in Intensive Care unit_APAER_H Protocol","APAER_H","Inclusion Criteria:\n\n* Subjects aged between 18 and 75 years old\n* Admitted in Intensive Care Unit\n* Informed consent\n\nExclusion Criteria:\n\n* Contraindication for physical exercise\n* Inability to understand the French language (written and\u002For oral)\n* Ongoing involvement in another proprietary research protocol\n* Lack of affiliation to social security",{"count":156,"type":22},[83],"Adapted Physical Activity (APA) is accepted as an effective, recommended and beneficial supportive care for the health of people with cancer during the different phases of the disease. The objective of the project is to analyse the effect of APA programs (Classic, Exergaming and Relaxation) on the state anxiety of people with severe blood diseases admitted to Intensive Care Unit (ICU). Anxiety is a major affect in this context. The interest of the practice of APA for this public is to reduce the level of state anxiety and to limit the decline of functional capacities. The main objective of this work is to identify whether specific and\u002For complementary effects result from the use of biofeedback and\u002For Exergaming.",[592,28,593,594],"Adapted Physical Activity","Anxiety","Relaxation","2025-03-14",{"date":597,"type":35},"2025-03-17",{"date":599,"type":35},"2022-12-02",{"date":601,"type":22},"2027-01",{"name":603,"class":96},"Centre Hospitalier Régional Metz-Thionville"]